"We believe that the wide availability of Praxbind-and the robust data on its use-can provide patients and healthcare providers with greater assurance in their anticoagulation treatment decisions." "In the rare event of an emergency situation requiring reversal, treatment decisions must be made quickly and confidently," said Thomas Seck, M.D., vice president, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. Praxbind is indicated for patients treated with Pradaxa when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding.
Food and Drug Administration (FDA) has provided full approval for Praxbind® (idarucizumab), the specific reversal agent for Pradaxa® (dabigatran etexilate mesylate). « Click here to return to The MTM Review.RIDGEFIELD, Conn., Ap/PRNewswire/ - Boehringer Ingelheim today announced that the U.S. Jennings added that, since about 1% to 4% of users are likely to experience major bleeding episodes and another 1% of the group is likely to undergo emergency surgery, as many as 500,000 patients will require, within 5 years, drugs that can rapidly reverse anticoagulation. Jennings estimated that 23 million to 36 million patients in the developed world could be using the new anticoagulants by 2020. The special presentation, which occurred before the FDA approval of Praxbind was announced, was led by Lisa Jennings, PhD, professor and director of the Vascular Biology Center at the University of Tennessee Health Science Center in Memphis. A presentation recently at the annual Transcatheter Cardiovascular Therapeutics meeting suggested that the approval of reversal agents could increase use of the new anticoagulants for stroke prevention in patients with atrial fibrillation. Washington, DC-The FDA recently accelerated approval of an agent, Praxbind (idarucizumab), to reverse Pradaxa’s blood-thinning effects in an emergency situation.
0 kommentar(er)
